Overview of In Waves & War: Marcus & Amber Capone On Psychedelic Treatment For Veteran PTSD, Rebuilding Life After War & The Mission To Heal A Generation
This Rich Roll episode features Marcus and Amber Capone sharing their personal journey from special-operations life, trauma, addiction and marriage breakdown to profound healing through Ibogaine and psychedelic-assisted approaches. They discuss the lived experience of deployment and PTSD/TBI, why conventional treatments failed, what happened during Marcus’s Ibogaine ceremonies, the scientific signals (including Stanford imaging), and how they turned their recovery into service: Veterans Exploring Treatment Solutions (VETS) and the commercial/clinical platform Tara Mind. The conversation blends raw personal testimony, practical recommendations, research context, policy advocacy and resources for people in crisis.
Key takeaways
- Marcus (former Navy SEAL, instructor, multiple deployments) experienced severe PTSD/TBI, alcoholism and suicidal ideation; conventional psych meds and many brain clinics did not help.
- Ibogaine (an alkaloid from the iboga plant) produced a dramatic life-review experience for Marcus that he describes as lifting a lifelong “backpack” of guilt, shame and trauma. He reported sustained improvement and regained functioning.
- Stanford-affiliated research observed large improvements in PTSD/depression/anxiety scores and notable return of neurological function after Ibogaine in the small study cited — validating psychological and physiological effects (more research needed).
- Marcus and Amber founded VETS (nonprofit) to subsidize/guide veterans to proven psychedelic-assisted care and advocate for policy/research change. Tara Mind is a commercial platform to scale access via employers and clinics.
- Psychedelic-assisted treatments show promise for treatment-resistant conditions but carry risks (cardiac, regulatory, inexperienced providers); they require medical oversight and careful integration.
- Immediate crisis: call or text 988 (U.S. Suicide & Crisis Lifeline). For imminent suicidality or severe crisis, seek emergency/clinical help; ketamine clinics can be a medically supervised short-term option for stabilization.
Episode highlights / topics discussed
- Personal backstory: Marcus’s path from college athlete to SEAL, 13+ years in special operations, six deployments; Amber’s role as spouse, parent and caregiver.
- How trauma accumulated: battlefield losses, blast/subconcussive impacts, family strain, alcohol culture, and the slow “boil” of dysfunction after service.
- The turning point: a SEAL peer’s successful Ibogaine experience persuaded Marcus to try it after years of failed interventions.
- Description of Marcus’s Ibogaine experience: intense vomiting, life-review visions (dark trauma and recurrent light scenes with family), deep surrender, and long-term behavioral/neurological changes.
- Science & validation: Stanford Brain Stimulation Lab collaboration; reported symptom effect sizes of ~86–93% improvement in PTSD/depression/anxiety in the study described and imaging evidence of neurological recovery.
- Treatment models: differences between traditional Bwiti/iboga ceremonial models, Ibogaine dosing, and optional 5‑MeO‑DMT (“polish”) for some retreats — plus safety protocols and medical clearance.
- Advocacy & scale: policy wins (e.g., Texas screening, federal/state outreach), the documentary’s role in awareness, and ongoing efforts to integrate psychedelics into regulated clinical care.
- Integration work: importance of therapy, psychedelic integration coaches, breathwork, meditation, community, and lifestyle practices to sustain gains.
- Practical cautions: not a universal fix, not for those in acute uncontrolled medical/suicidal crises to undertake alone, drug interactions and cardiac screening required.
The Capones’ story (concise chronology)
- Met as teens/young adults; married after early military decisions.
- Marcus: watched GI Jane, joined SEALs, experienced intense deployments after 9/11; developed depression, memory/neurological issues, heavy drinking, and suicidal ideation.
- Amber: supported him through clinics and treatments, grew frustrated as family life deteriorated; learned of Ibogaine via a peer’s successful treatment and insisted Marcus try it as a last option.
- Marcus’s first Ibogaine (and subsequent) treatments led to major positive shifts: sobriety sustained, improved presence with family, and a drive to broaden access for others.
What is Ibogaine — Marcus’s experience described
- Source: alkaloid derived from the Tabernanthe iboga plant (West Africa/Bwiti tradition).
- Administration: oral dosing (pill/powder); requires medical screening (EKG, labs), cessation of certain meds (SSRIs) prior to dosing due to cardiac and interaction risks.
- Acute effects: intensified sensory experience, prolonged life-review visions, significant vomiting/purging often reported, intense psychological processing (can be the hardest experience some people ever face).
- Outcomes Marcus reported: relief from persistent guilt/shame, reduction in alcohol use/cravings, improved memory/organization, greater impulse control and sustained mood improvements.
- Integration: weeks/months of psychotherapy, lifestyle changes (breathwork, meditation, community), and occasional follow-up retreat dosing for maintenance (some patients return yearly).
Science & evidence mentioned
- Stanford Brain Stimulation Lab collaboration (Dr. Nolan Williams): reported large effect sizes on symptom scales (PTSD/depression/anxiety) and imaging showing return of neurological function after Ibogaine in their observational study.
- Key research themes:
- Psychedelics can reduce ego-driven narratives, enable perspective shifts, and re-open neuroplastic windows.
- Physiological effects: potential restoration of certain brain connectivity/function (promising but preliminary).
- Caveats: Most studies are small, observational or early-phase; more large-scale randomized controlled trials and safety studies are necessary.
VETS and Tara Mind — how they operate
- VETS (Veterans Exploring Treatment Solutions)
- 501(c)(3) nonprofit focused on veterans/special-operations community.
- Subsidizes clinically guided access to psychedelic-assisted treatments, provides integration support, spouse/family programming, ambassador networks, and policy/advocacy.
- Donor-dependent; demand greatly exceeds current capacity.
- Website/resource: vetsolutions.org
- Tara Mind
- Commercial/technology platform aimed at employers, clinics and payers.
- Builds a white-glove, concierge pathway to advanced psychiatric treatments (IV ketamine, TMS, and eventually psychedelic-assisted therapies) for employees and healthcare systems.
- Designed to scale clinical access and integrate with payers/employers.
Practical guidance, risks & recommendations
- Not a DIY approach: psychedelic treatments (esp. Ibogaine) require medical screening, dosing oversight, and integration therapy. Risk areas: cardiac effects, drug interactions (notably SSRIs), and safety of unsupervised use.
- Integration is critical: work with a licensed therapist or psychedelic integration coach after a retreat — especially during the 90-day neuroplastic window many programs emphasize.
- Crisis resources:
- Immediate suicide or acute crisis: U.S. call/text 988 (988 Suicide & Crisis Lifeline).
- For immediate stabilization of severe depression/suicidality, medically supervised IV or intramuscular ketamine at accredited clinics can be a viable short-term option.
- If considering treatment:
- Do thorough research; consult medical professionals and psychedelic-informed clinicians.
- Confirm clinic credentials, medical protocols, emergency procedures and aftercare/integration plans.
- Understand cost and access limitations; look into nonprofit supports (e.g., VETS) or employer benefits via platforms like Tara Mind.
Policy, access & ethical considerations
- Regulatory hurdles: Ibogaine is Schedule I in the U.S.; research and clinical access are limited. Clinical trials and FDA-regulated pathways are slow and expensive.
- Sustainability concerns: iboga plant sourcing and ecological pressures; some models use synthetic alkaloids to address scale/sustainability.
- Commercialization risks: potential for bad actors, commodification, and cultural appropriation of traditional Bwiti ceremonies; VETS and allies advocate for regulated, clinician-led access.
- Economic considerations: payers/insurers could drive broader adoption if long-term cost-savings (reduced hospitalizations, improved workforce productivity) are demonstrated.
Notable quotes & insights
- “The soldier is trained to identify the threat, and when they identify the threat as themselves, they may be trained to eliminate it.” — Amber, on suicide risk in trained warfighters.
- “I went from thinking this was crazy to, wait, this is medical treatment.” — Marcus, on shifting perception of Ibogaine.
- “It felt like being reunited with someone I hadn’t seen in over 15 years.” — Amber, describing seeing Marcus after his Ibogaine retreat.
- “Ibogaine closes the door on the past; 5‑MeO can open a door to the future” — synthesis of clinicians’ views shared in the episode.
How listeners can act / next steps
- Immediate help: if someone is in crisis, call/text 988 (U.S.) or go to emergency services.
- Learn more:
- VETS: vetsolutions.org — apply for support, donate, follow their advocacy.
- Look for local accredited ketamine clinics or advanced psychiatry centers for immediate stabilization options.
- Research vetted integration coaches and psychedelic-informed therapists before pursuing treatments.
- If you’re a clinician, policymaker, or donor: consider supporting research, clinical access, and veteran-focused programs that bridge science, safety and scaled access.
- Follow Marcus & Amber: they’ll launch a podcast “Conversations with the Capones” where they plan to share more on healing, relationships and recovery.
Final note
This episode blends a raw, human recovery story with emerging scientific data and practical pathways toward scaling psychedelic-assisted care for veterans and broader populations. The Capones stress caution, medical oversight and the importance of integration while urging policy and research progress so that more people can safely access treatments that show real promise for treatment-resistant trauma and depression.